Predictmedix Inc.'s Profile

Predictmedix is an Artificial Intelligence Company that has developed fast, non-invasive, contactless screeners that detect infectious diseases, impairment and even mental illness at any location where mass amounts of people gather such as: Hospitals, Stadiums, Airports, Malls, Government & Office Buildings.
Predictmedix Inc.
Symbol
PMED
Exchange
CSE
Shares
100,888,986 as of 10/30/2020
Industry
Technology & Medical
Create a Post

Top Members

MAIL ROOM
Last Posted:
08/30/2021
Rating:
Messages:
49

Predictmedix Inc.'s Bulletin

CALGARY, AB / ACCESSWIRE / September 8, 2021 / SBL Testing Technologies Inc. ("SBL") has partnered with Haztech Energy Corp (Canada) and Haztech USA LLC (USA) ( "Haztech") to significantly expand the delivery of Predictmedix's SAFE ENTRY Station technology to workplaces, governments, and organizations throughout North America. Founded in 2006 in Saskatchewan, Haztech has grown to one of the largest privately held occupational health & safety service providers in Canada. Haztech has further expanded their operations into the United States, with offices in Houston, Dallas and San Antonio Texas, as well as Denver, Colorado with further expansion plans across the USA. With Haztech's presence in Canada and the US, well-established clientele and aggressive growth, Haztech will immediately increase the exposure and adoption of the SAFE ENTRY technology. SAFE ENTRY Stations are powered by a proprietary, patent-pending artificial intelligence ("AI") algorithm developed by Predictmedix (CSE:PMED)(OTCQB:PMEDF) and manufactured by JuiceWorks. The clinically based AI was designed by data scientists and clinicians to identify multiple symptoms of infectious disease, displaying the result within seconds in the form of a red or green light. All screening is entirely autonomous and designed to protect the privacy of the end-user. "Haztech is the ideal partner to deliver the SAFE ENTRY technology. They understand workplace health and safety and have developed deep relationships with their extensive and impressive clientele. Haztech has the experience, resources and leadership to deliver a comprehensive infectious disease solution throughout North America, including the critical secondary assessments such as on-site rapid testing," commented Rich Robillard, Managing Director of SBL. Shawn Hazen, CEO of Haztech stated "SAFE ENTRY is an incredible screening technology for both short- and long-term pandemic response that brings safety and efficiencies for education, business, travel, sport and other public venues. The ability to objectively screen for infectious disease symptoms non-invasively and in seconds presents an entirely new first layer of risk mitigation that will improve the safety of people and communities." Rich Robillard further commented, "We are excited that two Canadian companies are delivering a Canadian developed and Canadian manufactured technology throughout North America. SAFE ENTRY is a timely solution that is increasingly critical as workplaces, governments and all organizations grapple with managing COVID-19 exposure risk, as well as planning for future infectious disease probability." About Haztech Haztech is a leading North American provider with services that include on-site doctors, nurses, and paramedics including remote access health centres, health & safety programs, occupational health testing, covid-19 testing, firefighting - rescue and emergency services, primary healthcare, medevac, security, safety training, and return-to-work injury management. For more information visit us online at www.haztech.com About SBL Testing Technologies Inc. SBL integrates innovative safety & testing technologies into complex workplaces, aligning to corporate risk profiles, safety programs and operational processes. SBL works with businesses, government agencies, and organizations in all industrial sectors globally, leveraging technology to reduce risk and enhance policy effectiveness. SBL's team has successfully provided risk management, safety solutions and testing technologies for decades, working with leading technology manufacturers from around the globe. SBL's Pandemic Response / Business Continuity solutions are led by a team who have successfully delivered fully integrated solutions to government agencies & Fortune 500 companies worldwide. For more information visit us online at www.sbltt.com Disclaimer: "Predictmedix is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain Covid-19 (or SARS-2 Coronavirus) at this time." SOURCE: SBL Testing Technologies Inc.  
Paras TechCare, a Division of Paras Defence, to Manufacture and Resell Safe Entry Stations into Indian Private and Public Sectors on Behalf of Predictmedix Paras Secured Two Initial High-Visibility Placements at Tier-1 Events in India; Serving as Launching Point for Near-Term Commercial Awareness in the Country TORONTO, ON / ACCESSWIRE / August 30, 2021 / Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) ("Predictmedix" or the "Company"), an emerging provider of rapid health screening solutions powered by a proprietary artificial intelligence (AI), today announced a strategic partnership with Paras TechCare, a division of Paras Defence & Space Technologies Ltd ("Paras"), under which Paras will manufacture, market, sell and distribute Predictmedix's proprietary Safe Entry Stations in a turnkey manner for deployment in the public sector throughout Paras is one of the largest providers of defense related technologies to the Indian government and has clientele extending into other Asian and Middle Eastern countries. The Company is an approved registered vendor to almost all government and public sector departments throughout India. The Company's Paras TechCare division leverages Paras' experience in manufacturing, as well as emerging technologies such as Predictmedix's Safe Entry Station, to combat the spread of COVID-19. Under the terms of the new reseller agreement, Paras TechCare will manufacture and sell Safe Entry Stations within the Southern Asian market on behalf of Predictmedix, where Paras maintains significant public sector relationships through its defense contractor business lines. "Predictmedix has been an ideal partner, offering incredible rapid health screening solutions that are becoming increasingly prominent within the Indian market," said Anish Mehta, Director at Paras Defence. "With screening applications from COVID-19 to impairment by drugs or alcohol, we see significant potential for this technology within the Indian public sector. I look forward to working closely with the Predictmedix team as we roll their technology out throughout Southern Asia." "We have been incredibly impressed with the capabilities and reach of the team at Paras, and are ready to enter a new phase of our strategic partnership," said Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix. "Allowing Paras TechCare to fabricate our platform in India will utilize their engineering expertise to help decrease production time, control costs and increase efficiencies. We are eager to leverage their established relationships in the government, targeting key public sector opportunities where our safety solution can add the most value. "In fact, through our relationship with Paras and the efforts of Mr. Guru Bakshish Singh Sehgal, Managing Director of Predictmedix (India), we already secured the placement of Safe Entry Stations for attendee screening at the widely followed 2021 Most Influential Personalities event - hosted by The Times of India and attended by celebrities, politicians and business leaders - as well as at the Forevermark Forum in late August, a leading diamond industry event in India hosted by the De Beers group of companies, where 80,000 diamonds are expected to be transacted over 3 days. We expect these to serve as a launching point for expanded near-term commercial awareness in the Indian market. I look forward to a long and successful partnership with Paras, with the ultimate goal of creating value for our shareholders," concluded Kushwah. About Paras Defence & Space Technologies Ltd.Paras Defence and Space Technologies Limited manufactures defense electronics and space application products. The Company offers defense automation and control, rugged displays, computing, sensors, missile motors, rockets, telescopes, guns and ammunition as well as special purpose machineries. For more information, please visit our website at www.parasdefence.com. About Predictmedix Inc.Predictmedix (CSE:PMED)(OTCQB:PMEDF) is a leading provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn. Investor Relations ContactLucas A. ZimmermanMZ Group - MZ North America949-259-4987PMEDF@mzgroup.uswww.mzgroup.us Caution Regarding Forward-Looking Information: THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law. Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time." SOURCE: Predictmedix   
Revenue-Generating Placement to Serve as Live Demonstration of Safe Entry Station to Tier-1 Government Agencies and Event Organizers TORONTO, ON / ACCESSWIRE / August 26, 2021 / Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) ("Predictmedix" or the "Company"), an emerging provider of rapid health screening solutions powered by a proprietary artificial intelligence (AI), today announced the revenue-generating deployment of four (4) Safe Entry Stations at the Palm Tree Music Festival to be held August 29, 2021 in Westhampton Beach, NY, as part of the Company's reseller partnership with the U.S.-based JUICEWORKS. The venue will serve as a unique opportunity to demonstrate the Company's proprietary AI-enabled screening solution to representatives from local, state and federal government agencies, the military and tier-1 event organizers in attendance. The single-day Palm Tree Music Festival will be an intimate festival experience designed to capture the unmatched feeling of summer in paradise with majestic beach vibes and unmissable sets by a lineup of global icons. The Palm Tree Crew partnered with Predictmedix and Northwell Health, New York's largest Health Care provider, to design a safety protocol for attendees. Upon arrival, guests and staff will be required to show proof of vaccination, along with a current PCR test. They will then walk through the Predictmedix Safe Entry Station to rapidly identify multiple symptoms of infectious diseases such as COVID-19, displaying the result in the form of a red or green light. "We knew that in order to bring this festival to life and provide a safe environment, we needed to partner with leaders in health and tech," said Myles Shear, Co-Founder of Palm Tree Crew. "We built Palm Tree Crew to create game-changing business ventures and I'm glad that we are able to partner with Predictmedix for this event." "We are rapidly becoming the preferred onsite solution for large scale live events globally, and the Palm Tree Music Festival represents an ideal opportunity to further showcase our technology to a variety of potential government and event organizer customers," said Dr. Rahul Kushwah, Chief Operating Officer at Predictmedix. "We expect to meet with multiple representatives from the armed forces, local, state and federal governments, government agencies, private security companies and major event providers to explain how they can utilize our proprietary AI algorithm to provide rapid, robust, and non-invasive screening, including multi-symptom detection of infectious diseases such as COVID-19. We look forward to the event as a real time use case for these potential customers and to protect the attendees at this exciting festival." About Predictmedix Inc. Predictmedix (CSE:PMED)(OTCQB:PMEDF) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn. Investor Relations ContactLucas A. ZimmermanMZ Group - MZ North America949-259-4987PMEDF@mzgroup.uswww.mzgroup.us Caution Regarding Forward-Looking Information: THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law. The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. SOURCE: Predictmedix